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Age groupsBackground: Factors, such as age, comorbidities, vaccine type, herd immunity, previous influenza expo-
sure, and antigenic shift may impact the immune response to the influenza vaccine, protection against
circulating strains, and antibody waning. Evaluating vaccine effectiveness (VE) is important for informing
timing of vaccine administration and evaluating overall vaccine benefit.
Methods: VEwas assessed using febrile respiratory illness surveillance amongDepartment of Defense non-
active duty beneficiaries from influenza seasons 2010–2011 through 2013–2014. Respiratory specimens
were taken from participants meeting the case definition and tested by polymerase chain reaction for
influenza. VE was calculated using logistic regression and by taking 1 minus the odds ratio of being vacci-
nated in the laboratory confirmed positive influenza cases versus laboratory confirmed negative controls.
Results: This study included 1486 participants. We found an overall adjusted VE that provided significant
and fairly consistent protection ranging from 54% to 67% during 0–180 days postvaccination. This VE
dropped to 11% (95% confidence interval: 102% to 39%) during 181–365 days.
Conclusions: Our study found moderate VE up to 6 months postvaccination. Since the influenza season
starts at different times each year, optimal timing is difficult to predict. Consequently, early influenza vac-
cination may still offer the best overall protection.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Each year roughly 5–20% of the US population is infected with
influenza, resulting in an estimated 3000–49,000 deaths [1]. The
best way to prevent influenza-associated disease burden is vacci-
nation; therefore, as of 2010, influenza vaccination has been rec-
ommended for everyone in the United States, 6 months of age
and older [2]. Yearly revaccination is necessary because circulating
strains and/or vaccine composition change every influenza season.
Additionally, previous studies have found that influenza vaccine
effectiveness (VE) declines over time since vaccination in some
populations does not provide significant protection in most cases
after 90–120 days [3–7]. Many factors impact VE estimates and
speed of decline – including age, comorbidities, herd immunity,
use of adjuvants, type of vaccine administered (live attenuated or
inactivated), prior natural influenza exposure, prior influenza
vaccination, antigenic drift, and study design [6,8–13].Previous studies have assessed influenza VE declines in rela-
tively small sample sizes or from 1 influenza season [3–6,14]. Addi-
tionally, many of these studies have been conducted outside the
United States, in regions that have different vaccine composition
(adjuvant vs. non-adjuvanted) [6,15], and vaccine recommenda-
tions [2,16], and may also have differences in circulating strains
and in the proportion of LAIV vs. IIV and quadrivalent versus triva-
lent vaccine which is administered. The goal of this study is to eval-
uate VE over time among US Department of Defense (DoD)
beneficiaries during 4 influenza seasons. Gaining a better under-
standing of postvaccination immunity declines is important for
evaluating the benefit of the vaccine and planning the timing of
vaccine administration.2. Methods
2.1. Study participants
Participants were selected from the Naval Health Research
Center’s (NHRC) febrile respiratory illness surveillance of DoD
non-active duty beneficiaries. The surveillance sites included Naval
Table 1
Descriptive characteristics among cases (influenza positive) and controls (influenza
negative), excluding those <15 days or >365 days postvaccination, n = 1481.
Characteristic Cases, n = 387
(%)
Controls, n = 1094
(%)
p value
Age group (years) <0.001
0–4 72 (19) 400 (37)
5–24 206 (53) 436 (40)
25–49 67 (17) 161 (15)
50–64 37 (10) 86 (8)
>64 5 (1) 11 (1)
Sex (% Men) 173 (45) 490 (45) 0.965
Influenza vaccine (% Yes) 91 (24) 521 (48) <0.001
Mean ± SD vaccination days 119 ± 56 108 ± 52 0.063
Influenza vaccine type (% IIV) 69 (76) 407 (79) 0.471
Influenza season <0.001
2010–2011 76 (20) 118 (11)
2011–2012 94 (24) 211 (19)
2012–2013 137 (35) 294 (27)
2013–2014 80 (21) 471 (43)
Calendar season 0.002
November–December 83 (21) 199 (18)
January–February 199 (51) 487 (45)
March–June 105 (27) 408 (37)
Abbreviations: IIV, inactivated influenza vaccine; SD, standard deviation.
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KearnyMesa, SanDiego, California; Naval Hospital CampPendleton,
Oceanside, California; and Captain James A. Lovell Federal Health
Care Center, North Chicago, Illinois. The case definition for febrile
respiratory illness is a personpresenting at anoutpatient health care
facility with an oral temperatureP38.1 C (100.5 F) or subjective
fever, and either cough or sore throat. A convenience sample of up
to 20 cases per week per site were enrolled (with sampling depen-
dent upon study staffing hours, resulting in a near random sample)
withnasal, combinationnasal/throat, or nasopharyngeal swabs dur-
ing influenza seasons 2010–2011 through 2013–2014. Samples
were frozen and sent to NHRC for testing every 1–2 weeks along
withde-identified casedata. Vaccinehistory, includingvaccine type,
and date of vaccination were collected frommedical records and/or
recall. Cases tested positive for influenza by real-time polymerase
chain reaction (qPCR), and controls tested negative for influenza.
Briefly, separate qPCR assays were performed for influenza A and B
using standard extraction methods and with primers provided by
the Centers for Disease Control. Influenza A positive samples were
further tested by CDC primers to determine subtype [influenza A
(H3N2) or A(pH1N1)]. Viral culture was performed on a subset of
influenza-negative samples using a rhesus monkey kidney cell line
to ensure that qPCR assays remained sensitive.
This study included participants enrolled during seasonal epi-
demic influenza periods, which were defined as times of consistent
circulation and identification of influenza positive cases. Partici-
pants with unknown influenza vaccine status or known influenza
vaccine status but unknown vaccine date were excluded, as were
those vaccinated <15 days or >365 days before sampling.
This research was conducted in compliance with all applicable
federal and international regulations governing the protection of
human subjects in research (Protocol NHRC.2007.0024). Partici-
pants gave written informed consent or parental informed consent
if underage. Since all specimens in this study were collected previ-
ously and were de-identified for the purposes of this study, the
NHRC institutional review board committee classified this study
as minimal risk, exempt from full committee review.
2.2. Statistical analysis
Chi-squared and analysis of variance tests were used to compare
the characteristics of cases and controls (Table 1). VEwas calculated
using logistic regression andby taking 1minus the odds ratio (OR) of
being vaccinatedmultiplied by 100 in the cases versus controls. The
following variables were assessed in the adjusted VE model: age
group (0–4 years, 5–24 years, 25–49 years, 50–64 years, and
P65 years), gender, influenza season (2010–2011, 2011–2012,
2012–2013, 2013–2014), and calendar season (November–Decem-
ber, January–February, March–June). Confounders (>10% change in
OR) or variables with P < .05 in the multivariate model were left in
the final adjusted model. The final model adjusted for age group
(0–4, 5–24, 25–49, 50–64, and >64 years), calendar season, and
influenza season. Overall VE estimateswere also stratified by partic-
ipants who were 0–14, 15–30, 31–60, 61–90, 91–180, and 181–
365 days postvaccination. Additionally, age group (0–4, 5–24, and
P25 years), type of vaccine (inactivated influenza vaccine [IIV] ver-
sus live-attenuated influenza vaccine [LAIV]), influenza subtype,
influenza season, and month stratifications were run for 15–90,
91–180, and 180–365 days postvaccination (Supplementary Table 1
and Figs. 1–3). SAS version 9.3 was used for all statistical analyses
(SAS Institute Inc., Cary, North Carolina).
3. Results
During the 4 influenza seasons examined for our study, 1720
participants meeting the febrile respiratory illness case definitionwere enrolled, with 198 were excluded due to incomplete vaccina-
tion history, 36 were excluded due to vaccination <15 days before
diagnosis, 5 excluded due to vaccination >365 days after diagnosis.
Among the remaining 1481 participants, 387 (26%) were cases
(influenza qPCR positive), and 1094 (74%) were controls (influenza
negative). Viral culture testing of a subset of qPCR-negative sam-
ples showed that qPCR sensitivity remained high (>99%) through-
out the study. Twenty-four percent of the cases and 48% of the
controls were vaccinated. Among those vaccinated, mean vaccina-
tion days were similar for cases (119 days) and controls (108 days)
(P = .063). The percentage of participants receiving IIV vaccination
was very similar in both groups, with 76% among cases and 79%
among controls (P = .471). There were some differences in the pro-
portion of cases versus controls across influenza seasons, likely
suggesting differences in flu severity or vaccine match from season
to season. The majority (53%) of the cases occurred in the 5–
24 year age group. Both cases and controls had similar percentages
of men and women (P = .965; Table 1).
Age, influenza season, and calendar season were all statistically
significant in the multivariate logistic regression model. Age group
was the only variable that was also a confounder. During the 0–14,
15–30, 31–60, 61–90, and 91–180-day intervals, overall VE esti-
mates were fairly constant, with VE estimates fluctuating from
53% to 67% and remaining significant. After 180 days, overall
adjusted VE estimates dropped to 16% (95% confidence interval
[CI]: 117% to 38%) (Supplementary Table 1 and Fig. 1).
Stratified analyses by vaccine type, age group, and influenza
subtype revealed no significant differences between adjusted VE
during the 15–90 and 91–180 days postvaccination time periods,
with a marked decrease in VE after 180 days. Exceptions were seen
in 2 subgroups (25 years of age and older; A/pH1N1 subtype) that
did not show a marked decrease in VE point estimates after
180 days, although confidence intervals were wide for these inter-
vals (Supplementary Table 1 and Fig. 1).
Our study found slightly lower adjusted VE point estimates
later in the influenza season (March, April, May) compared with
early in the influenza season (December, January, February), as
the ratio for percent influenza positive between unvaccinated
and vaccinated groups became incrementally smaller until being
nearly identical in May (Fig. 2).
Fig. 1. Adjusteda influenza vaccine effectivenessb estimates (95% CI) by days postvaccination, overall and stratified by influenza vaccine type, age group, and influenza
subtype. Data from 2010–2011 through 2013–2014. Abbreviations: CI, confidence interval; IIV, inactivated influenza vaccine; LAIV, live-attenuated influenza vaccine. aLogistic
regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years), calendar season (November–December, January–February, March–
June), and influenza season (2010–2011, 2011–2012, 2012–2013, 2013–2014), unless already stratified by that variable. bVaccine effectiveness = (1  Odds Ratio)  100.
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similar trends with higher protection during the 15–90 and 90–
180-day periods compared with >180-day period. VE estimates
during the 15–180-day period ranged from 54% to 70% and were
statistically significant for all influenza seasons except 2010–
2011 (Fig. 3).
4. Discussion
Comparing VE declines across studies can be difficult due to
variations in vaccine group recommendations, type of vaccine used
(adjuvanted versus unadjuvanted, IIV versus LAIV), herd immunity,
prior vaccination, regional circulating strains, timing of the influ-
enza season, vaccine match, and study design. Previous studies
have found declines in VE for influenza A (H3N2) over time, with
their VE estimates showing non-significant protection from the
vaccine after several months [3–7] or evidence for increased infec-
tion with longer time since vaccination [14]. However, some ofthese studies had relatively small sample sizes and thus may have
been underpowered to identify statistically significant VE even
when it existed. This study is the first to assess waning influenza
VE over time by examining 4 seasons of influenza data and looking
at multiple subtypes in the United States.
Unlike prior VE studies, our study showed significant influenza
vaccine protection up to 6 months postvaccination with only
slight, but not significant, declines in some stratified VE estimates.
The longer protection found in our study is supported by a similar
study which found that influenza hemagglutinin (HA) and neu-
raminidase (NA) titers declined slowly over 18 months following
influenza vaccination [17]. Surprisingly, our study even found
moderate VE estimates during the first 2 weeks postvaccination,
which is the period during which antibodies develop and HA and
NA titers increase [1].
During 181–365 days postvaccination, our study showed signif-
icant declines in protection with overall adjusted VE equal to 16%
(95% CI: 117% to 38%) (Table 1 and Fig. 1). Previous studies
Fig. 2. Influenza percent positivity among vaccinated and non-vaccinated individuals and adjusteda influenza vaccine effectiveness with 95% CI, stratified by month of illness.
Abbreviation: CI, confidence interval. aLogistic regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years) and influenza season
(2010–2011, 2011–2012, 2012–2013, 2013–2014). b Influenza vaccine effectiveness for May is equal to 66 (95% CI: 768 to 68). No vaccinated cases were identified in
November or June.
Fig. 3. Adjusteda influenza vaccine effectivenessb estimates (95% CI) by days postvaccination, stratified by influenza season. Abbreviation: CI, confidence interval. aLogistic
regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years) and calendar season (November–December, January–February, March–
June). bVaccine effectiveness = (1  Odds Ratio)  100. Note: Red dot indicates combined days post vaccination (15–180). (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
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have yielded mixed results. One study conducted in the United
States found that the monovalent pH1N1 vaccine provided no pro-tection from pH1N1 in the 2010–2011 influenza season [18]. How-
ever, another US study found similar VE estimates among those
vaccinated in the previous season only compared with those vacci-
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essary to evaluate protection P6 months postvaccination.
Our results coincide with those of other studies, which have
also found lower VE point estimates later in the influenza season.
Previous studies have postulated that these declines are the result
of antigenic drift or waning immunity [3–6]. Although percent pos-
itivity among vaccinated individuals remained relatively constant,
the overall amount of circulating influenza was lower at the end of
the season, reflecting the decline in VE estimates (Fig. 2).
Our study used a laboratory qPCR confirmed positive and nega-
tive control design of febrile respiratory cases presenting at outpa-
tient clinics. This is a common method of collecting case and
control data for VE studies, and is the method used by the CDC
for their annual VE estimates [19]. Certain times of year may have
less influenza and more other respiratory illness, therefore result-
ing in a greater number of controls and skewed VE estimates [20].
To deal with this, we restricted our analysis to periods of seasonal
epidemic influenza periods.
There have also been mixed results for the effect of repeated
vaccination on protection from influenza infection. One study
found that participants, who were vaccinated in the current influ-
enza season but infrequently vaccinated or not vaccinated in any of
the previous 5 influenza seasons, had higher VE compared with
those who were routinely vaccinated [13]. However, serological
studies have not provided evidence for lower protection in those
receiving routine annual influenza vaccinations [21]. Although
we did not have data on prior vaccination history and were not
able to control for it in our models, it is possible that this variable
impacted our VE estimates.
Another potential reason for differences between our results
and those of previous studies is variances in vaccine type and com-
position. Although our study showed similar VE estimates for IIV
versus LAIV, previous studies have shown that LAIV produces sig-
nificantly higher vaccine efficacy among children compared with
IIV [9]. Additionally, the use of adjuvant in flu vaccines may play
a role in VE estimates and comparability of our study with prior
ones done in Europe: during the 2011–2012 influenza season, 2
adjuvanted vaccines were licensed for use in the European Union
[15] and in the Kissling study, 4 of the 16 vaccines used contained
adjuvant [6]. Previous studies have shown that adjuvanted vacci-
nes result in significantly higher vaccine effectiveness than non-
adjuvanted vaccines in the elderly [10,11]. Since adjuvanted vacci-
nes are not licensed for use in the United States, we would have
expected the other European studies to have slightly higher VE
estimates over time than our study; however, this was not the
case.
Differences in vaccination recommendations and coverage
between the United States and other countries may also explain
our study’s higher VE estimates. The United States recommends
universal influenza vaccination of all individuals older than
6 months of age [2]; whereas other countries, such as Spain, rec-
ommend the vaccine and offer it free of cost for people older than
60 years of age and those with risk factors [3,16]. Older popula-
tions are especially vulnerable to waning immunity after vaccina-
tion as a result of immunosenescence or deterioration of the
immune system with age. If the elderly and people with comor-
bidities are more likely to get vaccinated than those without
comorbidities, they may also be more likely to have impaired
immune responses, thus biasing the VE estimates. Additionally, if
less people overall are vaccinated, herd immunity will likely be
lower in these populations, thereby also lowering VE estimates.
Variances in natural exposure to influenza and prior antibodies
may influence immune response to the influenza vaccine and VE
estimates, especially in the elderly. A study of elderly individuals
who were seronegative before vaccination found that they did
not accumulate enough antibodies from 1 vaccine influenza dose[12]. Another study found that low prevaccination antibody titers
and greater age were associated with faster titer declines postvac-
cination [8]. Consequently, cohort effects might exist with certain
age groups or with geographical populations having higher natural
exposure or prior antibodies and therefore better protection
against certain strains and improved response to the vaccine. We
controlled for some of these factors by adjusting for age and influ-
enza season in our model; however, we were not able to conduct
elderly-stratified analyses due to the small sample size for this
age group, as this study did not include any Veteran’s Administra-
tion facilities that serve most of the retired military population.
The US Advisory Committee on Immunization Practices recom-
mends that children who are aged 6 months through 8 years
receive 2 doses of influenza vaccine [22]. However, in our study,
only 27% of the children in this age range had received 2 doses of
the influenza vaccine at the time of illness. Consequently, VE esti-
mates for this age group are likely lower than if we had only
included children who had completed the full vaccine course. Sim-
ilarly, a high-dose influenza vaccine was recommended to individ-
uals 65 years and older beginning in 2010–2011 and believed to
improve protection in the elderly [23]. Unfortunately, we did not
have data on the proportion who received the higher-dose vaccine.
Another limitation of our study is that we did not conduct a
phylogenetic analysis of circulating strains to assess the degree
of antigenic drift from year to year. This may be a factor which
impacts declines in immunity over time. However, 1 study that
performed a phylogenetic assessment of circulating strains did
not find any antigenic drift at the end of the season, suggesting that
the declines were a result of waning immunity [4]. Other studies
have tried to assess the impact of antigenic drift by conducting a
separate analysis for early and late season VE and have found lower
VE in the late season, which may be reflective of antigenic drift [6].
We controlled for the potential impact of antigenic drift by adjust-
ing for calendar season in our adjusted model.
This study gathered data from a well-established respiratory ill-
ness surveillance system. The consistency of this surveillance sys-
tem allowed for robust comparisons across influenza seasons
which have not been done before. When comparing influenza sea-
sons, we found similar trends for each influenza season, with
higher protection during 15–180 days postvaccination and decli-
nes after this period. We also observed lower VE estimates during
the 2010–2011 season, which may correspond to antigenic drift of
the pH1N1 strain during this influenza season [24] (Fig. 3).
Our results suggest that administering influenza vaccines closer
to the start of the influenza season may increase VE slightly in
some groups. However, we also found that the flu vaccine offered
moderate and significant protection against influenza infection
for the duration of the influenza season or up to 6 months postvac-
cination. Since the start of the flu season varies each year, it is
somewhat difficult to predict the most opportune time to vaccinate
each year. Consequently, early vaccine administration in the fall
(before the start of the flu season) may still prevent the greatest
number of influenza infections.Financial support
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